[Pre-Aug 2018] IMSCAR
- Commissioned report › Research › Not peer-reviewed
- Published
A study of the effects of the Carers Strategy in Wales on the needs of carers and the services they receive
Seddon, D., Robinson, C. A., Russell, I. T., Woods, R. T., Tommis, Y., Reeves, C., Perry, J. K. & Boyle, M., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report